To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

And more pharma news updates from Pharmalittle.

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

Matcha, a vibrant green tea powder with ancient Japanese roots, has exploded in popularity worldwide. From traditional tea ...

In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

A new laboratory method developed by researchers at Columbia University Vagelos College of Physicians and Surgeons may now ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

The decision to block Alzheimer’s ‘wonder’ drugs for use by NHS patients will be appealed against. The two breakthrough drugs ...